Sabine Stegmaier1, Ivo Leuschner2, Christopher Poremba3, Ruth Ladenstein4, Bernarda Kazanowska5, Gustaf Ljungman6, Monika Scheer1, Bernd Blank1, Stefan Bielack1, Thomas Klingebiel7, Ewa Koscielniak1. 1. Klinikum Stuttgart, Olgahospital, Pediatrics 5 (Oncology, Hematology, Immunology), Stuttgart, Germany. 2. Kiel Paediatric Tumor Registry, Department of Paediatric Pathology, University of Kiel, Kiel, Germany. 3. Institute of Pathology Munich-Nord, Munich, Germany. 4. St Anna Kinderspital, Vienna, Austria. 5. Department of Pediatric Bone Marrow Transplantation, Oncology and Hematology Wroclaw Medical University, Wroclaw, Poland. 6. Department of Women's and Children's Health, Pediatric Hematology and Oncology, Uppsala University, Uppsala, Sweden. 7. Department of Pediatric Oncology, University of Frankfurt (Main), Frankfurt, Germany.
Abstract
BACKGROUND: The aim of our analysis was the evaluation of the prognostic impact of SYT-SSX fusion status and histological grading in synovial sarcoma (SS) of children and adolescents in the context of the consistent multimodal treatment strategy of the CWS (Cooperative Weichteilsarkom Studie; Cooperative Soft Tissue Sarcoma Study Group) and in comparison with other risk factors. PROCEDURE: Between 1986 and 2006, out of 243 patients with SS, tumor samples from 84 patients with localized disease were available for RT-PCR analysis. Outcome depending on fusion status in the context with known clinical risk factors was analyzed. RESULTS: No prognostic significance was shown for SYT-SSX fusion status and for histological grade. Highest significance of negative prognostic impact was found for large tumor size in uni- and multivariate analysis (P < 0.01). Furthermore, male gender was shown to be an adverse prognostic factor in multivariate analysis (P = 0.01). CONCLUSIONS: Based on our results, neither histological grading nor SYT-SSX fusion status seems to be suitable for outcome prediction and risk stratification in localized SS treated according to the CWS. This is in contrast to several other publications concerning more heterogeneous age groups including children and adults, and this indicates that prognostic factors should not be interpreted apart from the particular study population and the therapeutic context.
BACKGROUND: The aim of our analysis was the evaluation of the prognostic impact of SYT-SSX fusion status and histological grading in synovial sarcoma (SS) of children and adolescents in the context of the consistent multimodal treatment strategy of the CWS (Cooperative Weichteilsarkom Studie; Cooperative Soft Tissue Sarcoma Study Group) and in comparison with other risk factors. PROCEDURE: Between 1986 and 2006, out of 243 patients with SS, tumor samples from 84 patients with localized disease were available for RT-PCR analysis. Outcome depending on fusion status in the context with known clinical risk factors was analyzed. RESULTS: No prognostic significance was shown for SYT-SSX fusion status and for histological grade. Highest significance of negative prognostic impact was found for large tumor size in uni- and multivariate analysis (P < 0.01). Furthermore, male gender was shown to be an adverse prognostic factor in multivariate analysis (P = 0.01). CONCLUSIONS: Based on our results, neither histological grading nor SYT-SSX fusion status seems to be suitable for outcome prediction and risk stratification in localized SS treated according to the CWS. This is in contrast to several other publications concerning more heterogeneous age groups including children and adults, and this indicates that prognostic factors should not be interpreted apart from the particular study population and the therapeutic context.
Authors: Andrea Ferrari; Yueh-Yun Chi; Gian Luca De Salvo; Daniel Orbach; Bernadette Brennan; R Lor Randall; M Beth McCarville; Jennifer O Black; Rita Alaggio; Douglas S Hawkins; Gianni Bisogno; Sheri L Spunt Journal: Eur J Cancer Date: 2017-04-07 Impact factor: 9.162
Authors: Rajkumar Venkatramani; Wei Xue; R Lor Randall; Suzanne Wolden; James Anderson; Dolores Lopez-Terrada; Jennifer Black; Simon C Kao; Barry Shulkin; Andrew Ostrenga; Alberto Pappo; Sheri L Spunt Journal: J Clin Oncol Date: 2021-10-08 Impact factor: 44.544
Authors: Vancheswaran Gopalakrishnan; Behrang Amini; Michael J Wagner; Erica N Nowell; Alexander J Lazar; Patrick P Lin; Robert S Benjamin; Dejka M Araujo Journal: Sarcoma Date: 2017-06-05
Authors: Adam J Eqbal; Laura Goodliffe; Hassan Masoom; Muhammad Ajlan; Jessica Hanna; Snezana Vukmirovic-Popovic; Ashwin Philips; Emilie P Belley-Côté; Omid Salehian; Richard P Whitlock Journal: JACC Case Rep Date: 2022-08-17
Authors: Monika Scheer; Christian Vokuhl; Sebastian Bauer; Jörg Fuchs; Steffan Loff; Beate Timmermann; Marc Münter; Anton George Henssen; Bernarda Kazanowska; Felix Niggli; Ruth Ladenstein; Gustaf Ljungman; Ewa Koscielniak; Thomas Klingebiel Journal: J Cancer Res Clin Oncol Date: 2021-07-17 Impact factor: 4.553